¿Por qué Entresto®? 

Referencias

1. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysininhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25176015/ 2. Januzzi JL Jr,et al. PROVE-HF Investigators. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1085-1095. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31475295/ 3. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. Can J Cardiol. 2021;37(2):292-299. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31240976/ 4. Rohde LE, et al. PARADIGM-HF Investigators. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. Circulation. 2021;144(22):1805-1816. Disponible en:https://pubmed.ncbi.nlm.nih.gov/32919916/ 5. Desai AS, etal. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. JACC Heart Fail. 2016;4(9):692-700. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27417000/ 6. Damman K, Gori M,Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. Circulation. 2018;137(10):1128-1139. Disponible: https://pubmed.ncbi.nlm.nih.gov/29655829/ 7. Curtain JP, et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2020;22(6):1059-1068. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34969175/ 8. Wachter R, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early afterdischarge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21(8):998-1007. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31134724/ 9. Senni M, et al. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail. 2020;22(10):1846-1856. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31820537/ 10. Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019 Sep 17;322(11):1085. 10.1001/jama.2019.12821. 11. Docherty KF, Vaduganathan M, Solomon SD, McMurray JV. Sacubitril/Valsartan. JACC Heart Fail. 2020 Oct;8(10):800-10. 10.1016/j.jchf.2020.06.020. 12. The Galien Foundation. Available at: https://www.galienfoundation.…rnational-award-2-2/ (Accessed July 2022). 13. Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, Zieroth S, Butler J. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care? Can J Cardiol. 2021 Dec;37(12):1942-1953. Doi: 10.1016/j.cjca.2021.02.031. PMID: 34256518. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35663626/ 14. Khan MS, Butler J, Greene SJ. Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of 'too little, too late'. Eur J Heart Fail. 2021 Mar;23(3):360-363. doi: 10.1002/ejhf.2179. PMID: 33404183. disponible en: https://pubmed.ncbi.nlm.nih.gov/34286897/ 15. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014 Sep
11;371(11):993–1004.